Novartis’ Foradil 24 Mcg Dose Shows Improved Efficacy; Safety Questioned
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Foradil 24 mcg appears to offer a slight efficacy advantage over 12 mcg and would be approvable if Novartis could adequately address concerns about severe asthma exacerbations, Marianne Mann, MD, deputy director of the Division of Pulmonary and Allergy Drug Products, said in a Feb. 2 review of the Foradil NDA. The aerolized asthma drug was approved in a 12 mcg dose on Feb. 16.
You may also be interested in...
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
September 2010 Approvals
Product
Provenge Paradox Sparks New Thinking About Immunotherapy Trials, Clinical Care
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class